Article

RP-HPLC-ESI-QTOF-MS Qualitative Profiling, Antioxidant, Anti-Enzymatic, Anti-Inflammatory, and Non-Cytotoxic Properties of *Ephedra alata* Monjauzeana

Latifa Khattabi, Tarek Boudiar, Mustapha Mounir Bouhenna, Aziez Chettoum, Farid Chebrouk, Henni Chader, Jesus Lozano-Sánchez, Antonio Segura-Carretero, Gema Nieto, Salah Akkal

Abstract: An investigation was conducted to study the beneficial effects of *Ephedra alata* monjauzeana crude extract (EamCE). The chemical profile was determined using RP-HPLC–ESI-QTOF-MS analysis, revealing the presence of twenty-one flavonoids and phenolic acids. A series of antioxidant assays was carried out using four different methods. The EamCE has demonstrated a significant antioxidant potential, with interesting IC₅₀ values not exceeding 40 μg/mL in almost activities. Likewise, a significant inhibition of key enzymes, involved in some health issues, such as Alzheimer’s disease, diabetes, hyperpigmentation, dermatological disorders, gastric/urinary bacterial infections, and obesity, was observed for the first time. The IC₅₀ values ranged from 22.46 to 54.93. The anti-inflammatory and non-cytotoxic activities were assessed by heat-induced hemolysis and cell culture methods, respectively; the EamCE has shown a prominent effect in both tests, notably for the anti-inflammatory effect that was superior to the reference compound “diclofenac” (IC₅₀: 71.03 ± 1.38 > 70.23 ± 0.99 (μg/mL)).

According to these results, this plant could be used in a large spectrum as a food supplement, as a natural remedy for various physiological disorders and pathologies; and it might serve as a preventive and health care agent.

Keywords: *Ephedra alata* monjauzeana; chemical characterisation; biological virtues; crude extract

1. Introduction

Plants have been exploited since archaic ages in all countries and cultures, for their potential medicinal properties. The great civilizations of the ancient Chinese, Indians, and North Africans left written evidence of man’s experience in employing plants for the cure of a full range of sicknesses [1–3]. In our study, we have opted for *Ephedra alata* monjauzeana, a plant used by the Saharawi people of Algeria’s desert as herbal tea to help them sleep, relax, calm their anxiety, and reduce stress, hence the interest in deepening the knowledge of this plant and support of its traditional therapeutic use. The foliage of *Ephedra alata* (E. alata) has a pleasant aroma and has been used as foodstuff for animal grazing in Saudi
Arabia [4]; likewise, it presents a promising natural source of constituents that could be used as food additives [5,6]. Today, medicinal food plants are being prescribed in the form of complementary and alternative medicine therapies [7]. Indeed, natural products from plant origin, either as pure compounds or as standardized extracts afford durable source to design novel drugs [8–10]. Ephedra (family Ephedraceae, the joint firs) is a genus of non-flowering seed plants related to the Gnetales, the closest living relatives of the Angiosperms. Approximately 50 Ephedra species worldwide are shrubs adapted to semiarid and desert conditions. Around 25 species of Ephedra are encountered in the arid zones of the Old World spanning westwards from Central Asia across southwest Asia and into Mediterranean Europe and North Africa [11]. Moreover, E. alata, is a medicinal plant that grows mostly in the desert and is known to comprise approximately 40 species that populate dry environments; it has been frequently employed in traditional medicine in China and most Arabian countries, for diverse medical intents. In other respects, numerous secondary metabolites of E. alata, counting alkaloids, tannins, saponins, proanthocyanidins, phenolic acids, flavonoids, and essential oils, have been recorded, and the plants-derived polyphenols are of extreme interest for their high antioxidant activities [12,13]. In China, people used to apply it as a traditional medicine for 5000 years to treat allergies, bronchial asthma, chills, colds, coughs, edema, fever, flu, headaches, and nasal congestion [14].

The intentions of this first study on E. alata monjauzeana, taking into account earlier findings concerning other E. alata subspecies, were to confirm the same proven biological effects of E. alata. To the greatest extent, checking and characterizing new virtues and molecules that particularly define the plant of interest.

2. Materials and Methods

2.1. The Chemicals

Standards compounds (purity ≥ 95%), chlorogenic acid, quercetin-3-O-glucoside, kaempferol-3-O-glucoside, kaempferide, luteolin-7-O-glucoside, and apigenin were purchased from Sigma Aldrich (St. Louis, MO, USA). Syringic acid was sourced from Fluka-Chemika (Buchs, Switzerland). Stock solutions were prepared at 1 mg/mL in methanol and properly diluted before analysis. Solvents used for extraction and analysis were of analytical and HPLC-MS grades, respectively. Methanol, acetonitrile, and formic acid were obtained from Fisher Chemicals (Thermo Fisher, Waltham, MA, USA). Ultrapure water was obtained by a Milli-Q system (Millipore, Bedford, MA, USA). Acetylcholinesterase (AChE) type VI-S, from electric eel b1000 U/mg solid, Butyrylcholinesterase (BChE) from equine serum 100 U/mg solid, 5,5′-dithiobis[2-nitrobenzoic acid] (DTNB), butyrylthiocholine chloride, galantamine, 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2′-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS), linoleic acid, β-carotene, 2,6-di-tert-butyl-4-hydroxytoluene (BHA), tween 40, neocuproine, alpha amylase from aspergillus oryzae, 3-(3,4-dihydroxyphenyl-2,5,6-d3)-L-alanine (L-DOPA), kojic acid, thiourea, lipase from porcine pancreas, tyrosinase from mushroom ≥ 1000 U/mg solid, urease from Canavalia ensiformis (Jack bean) and other chemicals were Sigma Aldrich products and acetylthiocholine iodide was purchased from BioChemica.

2.2. Plant Material

The aerial parts of E. alata monjauzeana were collected during the flowering season from southeast of Algeria “Djebal Antar, Beni Abbes-Bechar”. The recovered quantity was stored in the departmental Herbarium (dark room at cool temperature) of the Biotechnology Research Center’s Health division. The plant was identified and authenticated according to the phenotypical features described by Dubuis and Faurel, in 1957 [15].

2.3. Extraction

The dried aerial parts of E. alata monjauzeana were grinded into a powder using a Microfine grinder Merke IK MF 10 Basic Staufen (DE) Germany. The EamCE was obtained by means of maceration with a mixture of methanol/water (80:20, v/v), under constant
stirring and left overnight in the dark. The maceration exudate was filtered, and the recovered solution was then evaporated under vacuum using a rotary evaporator at 35 °C. The process was repeated every 24 h, three times. The EamCE was dissolved in a small quantity of methanol/water (80:20, v/v) and eventually filtered through a 0.2 µm filter before its analysis.

2.4. RP-HPLC-ESI-QTOF-MS Analysis

MS Analyses were performed with an Agilent 1200 series rapid resolution (Agilent Technologies, Palo Alto, CA, USA) supplied by a binary pump, an auto sampler, and a diode array detector (DAD), using a quadrupole-time-of-flight mass spectrometry analyzer (QTOF, model 6540 Agilent Ultra-High-Definition Accurate-Mass Q-TOF), equipped with an electrospray ionization interface (ESI, model Agilent Dual Jet Stream interface). The flow amount was adjusted at 0.80 mL/min throughout the gradient. Then, 10 µL of the EamCE solution (20.000 mg/L) was injected. Separation was executed on a 150 × 4.6 mm, 1.8 µm, Zorbax Eclipse Plus C18 column (Agilent Technologies) at room temperature. Gradient elution was run, utilizing as eluent A: water with 0.1% formic acid and as eluent B: acetonitrile. The following multistage linear gradient was applied: 0 min, 5% B; 45 min, 100% B; 55 min, 5% B; and, finally, a conditioning cycle of 5 min, with the same conditions for the next analysis. The separated compounds were monitored in sequence first with the DAD and then with a mass spectrometry detector spectra that were acquired over a mass range from m/z 70 to 1100 operating in negative ionization mode. Internal mass correction was achieved with an unceasing infusion of Agilent TOF mixture consisting of trifluoroacetic acid, ammonium salt, and hexakis (1H,1H,3H-tetrafluoropropoxy) phosphazine. All spectra were calibrated prior to phytochemical identification. The detection window was set to 100 ppm. The MS and MS/MS data were processed using the Mass Hunter Qualitative Analysis B.06.00 software (Agilent Technologies) that yielded a list of eventual elemental formulas.

2.5. TPC, TFC, In Vitro Antioxidant Photoprotective and Anti-Enzymatic Activities

All experiments were realized in 96-well microplates, and the absorbance measurements were carried out on a Multimode Plate Reader, EnSpire, PerkinElmer, Waltham (US) United States of America. BHA, BHT, α-Tocopherol, ascorbic acid, tannic acid, gallic acid, quercetin, galantamine, acarbose, kojic acid, thiourea, and orlistat were used as standards (positive controls) to estimate the relative extract activity. The EamCE solution was prepared at seven different concentrations, (800, 400, 200, 100, 50, 25, 12.5 µg/mL) and every assay was realized in triplicate. The results were expressed as 50% inhibition (IC$_{50}$) and absorbance at 0.5 (A$_{0.5}$) concentrations that are able to inhibit/block/chelate 50% or reduce the absorbance to 0.5 of the radical, enzyme catalytic sites or the formation of metallic complexes/cations.

2.5.1. Total Phenolic Content (TPC) and Total Flavonoid Content (TFC) Assessment

TPC Dosage

The total phenolic content was assessed spectrophotometrically according to Folin–Ciocalteu method, modified by References [16,17], and the result was expressed as micrograms of gallic acid equivalents per milligram of extract (µg GAE/mg).

TFC Dosage

The total flavonoid content was assessed spectrophotometrically following the method described by Topçu et al. [18], and the result was expressed as micrograms quercetin equivalents per milligram of extract (µg QE/mg).
2.5.2. Estimation of Antioxidant Activities

**ABTS Scavenging Procedure**

The ABTS•⁺ scavenging ability was performed spectrophotometrically according to the modified procedure of Re et al. [19]. First, the ABTS•⁺ was prepared as follows: 2 mM of ABTS was dissolved in H₂O with 2.45 mM potassium persulfate (K₂S₂O₈), and the mixture was conserved at ambient temperature for 16 h in obscurity. Second, 160 µL of diluted ABTS•⁺ solution (delivering an absorbance value of 0.700 ± 0.025 at 734 nm) was added to 40 µL of EamCE solution. Thereafter, the microplate was incubated for 10 min before measuring the absorbance at 734 nm. The equation below (*) was used to calculate the inhibition percentage of ABTS radical, and results were presented as IC₅₀ values.

\[ I\% = \frac{(A_c - A_s)}{A_c} \times 100 \]  

\( I\% = ((A_c - A_s)/A_c) \times 100 \ (*) \) \hspace{1cm} (1)

**DPPH Scavenging Procedure**

The scavenging capacity of the stable DPPH free radical was indicated by the adjusted method of Blois [20]: 160 µL of DPPH solution (1 mM) in methanol was put in reaction with 40 µL of the EamCE solution; then, absorbance was measured at 517 nm after 30 min of incubation in the dark. Results were provided as IC₅₀ values, and the I% were calculated using the above formula (*).

**Superoxide Alkaline DMSO Test**

The superoxide radical was produced as described Kunchandy’s method [21]: 30 µL of NBT (nitroblue tetrazolium) (1 mg/mL) and 40 µL of sample were added to 130 µL alkaline DMSO (1.0 mL DMSO, 5 mM NaOH, 100 µL H₂O). The absorbance of the reaction mixture was measured at 560 nm, and results were provided as IC₅₀ values.

**Reducing Power Test**

To assess the reducing power effect, 10 µL of the EamCE solution were added to 40 µL of 0.2 M phosphate buffer (pH 6.6) and 50 µL of potassium ferricyanide (1%), incubated for 20 min at 50 °C. Later, 50 µL of TCA (trichloroacetic acid) (10%) and 10 µL of ferric chloride (0.1%) were added before finally measuring the mixture’s absorbance at 700 nm. The results were given as the EamCE concentration, giving an absorbance 0.5 (A0.5) [22].

**β-Carotene/Linoleic Acid Bleaching Test**

Proceeding as described by Marco [23], with minor changes: 0.5 mg of β-carotene, 1 mL of chloroform, 25 µL of linoleic acid, and 200 µL of Tween 40 were added, forming an emulsified mixture. Then, it was evaporated under vacuum, and 50 mL of hydrogen peroxide (30%) were added with vigorous shaking. The absorbance at 470 nm should give a value between (0.8–0.9). Next, 160 µL of the prepared β-carotene was added to 40 µL of EamCE solution. The 0 min (t₀) and 120 min (t₁₂₀) time absorbances were measured, and the results were given as IC₅₀ values, according to the following equation:

\[ I\% = 1 - \frac{(A_s (t_0) - A_s (t_{120}))}{(A_t (t_0) - A_t (t_{120}))} \times 100 \]  

\( I\% = 1- ((A_s (t_0) - A_s (t_{120}))/ (A_t (t_0) - A_t (t_{120}))) \times 100 \hspace{1cm} (2) \)

where As is the absorbance of the tested sample at t₀ (time = 0 min) and A (time = 120 min) of the reaction, and Ac is the absorbance of control (methanol) at t₀ (time = 0 min) and A (time = 120 min) of the reaction.
Cupric Reducing Antioxidant Capacity (CUPRAC) Assay

The method described by Reference [24] was used with no modifications. In brief, 10 mM of CuCl₂ (50 µL), 7.5 mM of neocuproine in ethanol (50 µL), and 1 M of CH₃COONH₄ (60 µL) with 40 µL of the EamCE solution was added simultaneously to generate the reaction, and the mixture was incubated for 1 h before measuring the absorbance at 450 nm. The result was given as A0.5 value.

Hydroxyl Radical Scavenging Assay

It was evaluated according to the modified method of Smirnoff and Cumbes [25]. Initially, 40 µL of the EamCE solution was mixed with 80 µL salicylic acid (3 mM), 24 µL FeSO₄ (8 mM), and 20 µL H₂O₂ (20 mM). The microplate was incubated for 30 min at 37 °C, and 36 µL H₂O was added; immediately, the absorbance was measured at 510 nm. The result was given as IC₅₀ value.

O-Phenanthroline Assay

As proceeded by Szydlowska-Czerniaka et al. [26], the reaction mixture held 30 µL o-phenanthroline (0.5% in methanol), 50 µL FeCl₃ (0.2%), 110 µL methanol, and 10 µL of the EamCE solution. Next, it was incubated for 20 min at 30 °C before measuring the absorbance at 510 nm. The result was given as A0.5 value.

Galvinoxyl Radical (GOR) Scavenging Assay

The procedure consisted of adding 160 µL of (0.1 mM) galvinoxyl in methanol to 40 µL of the EamCE solution, followed by an incubation of 120 min, and then the absorbance was read at 428 nm. The result was given as IC₅₀ value [27].

Silver Nanoparticle-Based Method

The reduction of Ag⁺ to spherical silver nanoparticles (SNPs) was developed by Özyürek et al. [28]. Firstly, 130 µL of SNP solution (prepared by heating 50 mL of AgNO₃ (1.0 mM) for 10 min; then, 5 mL of trisodium citrate (1%) was added drop by drop until a pale-yellow color was obtained) and 50 µL of H₂O were added to 20 µL of the EamCE solution. The microplate was incubated for 30 min at 25 °C, and the absorbance was read at 423 nm. The result was given as A0.5 value.

2.5.3. In Vitro Photoprotective Capacity

The photoprotective property of the EamCE was determined following the procedure reported by Cristina et al. [29]. It is expressed by the sun protection factor (SPF). The sample was dissolved in methanol at a concentration of 2 mg/mL (2000 ppm). Afterwards, the absorbance was recorded at seven different wavelengths with a 5 nm interval, from 290 to 320 nm.

SPF is the ratio calculated using the formula below:

\[
\text{SPF spectrophotometric} = \text{CF} \times \sum \text{EE(λ)} \times \text{I(λ)} \times \text{Abs(λ)}
\]  

EE: erythemal effect spectrum, I: solar intensity spectrum, Abs: absorbance of sunscreen product.

CF: correction factor (= 10).

The values of EE(λ) × I(λ) are constants determined by Sayre et al. [30] and are displayed in Table 1.
Table 1. Correlation between the erythemogenic effect (EE) and the radiation intensity at each wavelength (I) [29].

| Wavelength $\lambda$ (nm) | EE ($\lambda$) × I ($\lambda$) (Normalized) |
|---------------------------|--------------------------------------------|
| 290                       | 0.0150                                     |
| 295                       | 0.0817                                     |
| 300                       | 0.2874                                     |
| 305                       | 0.3278                                     |
| 310                       | 0.1864                                     |
| 315                       | 0.0837                                     |
| 320                       | 0.0180                                     |
| Total                     | 1                                          |

2.5.4. Anti-Enzymatic Activities

Evaluation of Anti-Acetylcholinesterase (AChE) and Anti-Butyrylcholinesterase (BChE) Activities

Anti-AChE and Anti-BChE inhibitory assays were evaluated using the method described previously in the work of Ellman and Öztürk [31,32]. Briefly, 150 $\mu$L of 100 mM sodium phosphate buffer (pH 8.0), 10 $\mu$L of the EamCE solution, and 20 $\mu$L AChE ($5.32 \times 10^{-3}$ U) or BChE ($6.85 \times 10^{-3}$U) were mixed. At this point, the mixture was incubated for 15 min at 25 °C; additionally, 10 $\mu$L of DTNB (0.5 mM) was added, and 10 $\mu$L of acetylthiocholine iodide (0.71 mM) or 10 $\mu$L of butyrylthiocholine chloride (0.2 mM) was added to initiate the reaction. The results were given as IC$_{50}$ values.

Anti-Alpha Amylase Potential

The anti-alpha amylase potential was assessed using the iodine/potassium iodide method, with few modifications [33]. To begin, the sample (25 $\mu$L) was mixed with an $\alpha$-amylase solution (1U (50 $\mu$L)) and then incubated at 37 °C for 10 min. After that, the reaction was started by adding a starch solution (50 $\mu$L, 0.1%). Concurrently, a control was prepared without putting the enzyme solution. After another incubation of 20 min at 37 °C, 25 $\mu$L HCl (1 M) and 100 $\mu$L iodine-potassium iodide solution were added successively to stop and assess the reaction by measuring the absorbances at 630 nm, and result was given as IC$_{50}$ value.

Tyrosinase Inhibition Ability

Tyrosinase inhibition ability was performed employing L-DOPA as substrate as detailed before [34]. First, 10 $\mu$L of the EamCE solution was mixed with 150 $\mu$L of sodium phosphate buffer (100 mM, pH 6.8) and 20 $\mu$L of tyrosinase enzyme solution (150 units/mL) and incubated for 10 min at room temperature. Then, 20 $\mu$L of L-DOPA (5 mM) was added to initiate the reaction; after that, the mixture was incubated further for 10 min at 37 °C before measuring the absorbance at 475 nm. The result was given as IC$_{50}$ value.

Urease Inhibition Capability

Urease inhibitory capability was determined by measuring ammonia production using the indophenol method [35]. Briefly, the reaction mixture consisted of 25 $\mu$L of enzyme solution ((5 U/mL) (Jack bean urease)), 10 $\mu$L of the EamCE solution, and 50 $\mu$L of urea substrate solution, then it was incubated at 30 °C for 15 min. Then, 45 $\mu$L of phenol reagent (2 g of phenol (C$_6$H$_5$OH) in 25 mL H$_2$O + 25 mg of Na$_2$[Fe(CN)$_5$NO]2H$_2$O in 25 mL H$_2$O) and 70 $\mu$L of basic reagent (0.7125 g of NaOH in 25 mL H$_2$O + 1.175 mL of NaOCl in 25 mL H$_2$O) were added later. After 50 min of incubation, the absorbance was measured at 630 nm, and result was given as IC$_{50}$ value.

Inhibitory Pancreatic Lipase Activity

Porcine pancreatic lipase (PPL, type II) activity was assessed employing p-nitrophenyl butyrate (p-NPB) as a substrate, according to the slightly modified protocols [36,37]. First,
100 µL of enzyme solution (1 mg/mL in 50 mM Tris-HCl (pH 8.0)) was added to 50 µL of the EamCE solution. Then, the microplate was kept for 20 min at 37 °C. Finally, 50 µL of p-NPB (5 mM) was added to initiate the reaction.

**Anti-Inflammatory Test by Heat-Induced Hemolysis Method**

An erythrocyte suspension was prepared as follows: a total human blood was obtained from a safe donor and then centrifuged for 5 min at 3000 rpm in heparinized centrifuge tubes. The suspension was washed three times with an equivalent volume of NaCl 0.9%. Subsequently, it was diluted to obtain a suspension of 10% (v/v) in an isotonic buffer solution (10 mM sodium phosphate buffer, pH 7.4). The procedure consists of adding 0.05 mL of the erythrocyte suspension and 0.05 mL of the EamCE solution mixed with 2.95 mL phosphate buffer (pH 7.4). The conical tubes were incubated at 54 °C for 20 min in a shaking water bath. Once this was done, they were centrifuged at 2500 rpm for 3 min, and the absorbance of the supernatant was measured at 540 nm against a control using phosphate buffer. Diclofenac (purchased from a pharmacy) was used as a reference compound [38]. The EamCE percentage inhibition was recorded according to the equation below:

\[
\% \text{ inhibition of hemolysis} = 100 - \left(1 \times \frac{C}{S}\right) \tag{4}
\]

where \(C\) = absorption of the control, and \(S\) = absorption of test sample mixture.

**2.5.5. Cytotoxic Test**

**Cell Culture**

Hep2 (Human epithelial type 2 (laryngeal carcinoma)) and Rd (rhabdomyosarcoma) × cells were kindly provided by Pasteur Institute, Algiers (DZ), Algeria. The cells were grown and maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal calf serum and 1% (v/v) antibiotic–antimycotic in a 37 °C, 5% CO₂ humidified atmosphere. The cells were harvested every 3 days. After thawing, the cells were kept in normal culture conditions for 10 days before experiments.

**Cytotoxicity Assessment**

Hep2 and Rd cells were incubated with different concentrations (15.625, 31.25, 62.5, 125, 250, 500 µg/mL) of the EamCE for 48- and 72-h periods. Hep2 and Rd cell viability was assessed by the MTT assay [39], where 100 µL of MTT was added and incubated at 37 °C for 4 h. The insoluble formazan was dissolved in 100 µL of DMSO. The absorbance was measured at 490 nm. All experiments and measurements were performed in triplicate.

The cytotoxic effect was determined using the below formula:

\[
\text{Cytotoxic effect (\% Cell inhibition)} = 1 - \left(\frac{Ac}{As}\right) \times 100 \tag{5}
\]

\(Ac\): absorbance of the control;
\(As\): absorbance of the sample.

**2.6. Statistical Analysis**

Results are expressed as the mean values ± SD of three measurements; the IC₅₀ and A0.50 values were calculated by linear regression analysis, and variance analyses were performed by ANOVA using XLSTAT. Significant differences between means were determined by Tukey test, and \(p\) values <0.05 were regarded as significant.

**3. Results**

The base peak chromatogram (BPC) of the EamCE in the negative ionization mode is presented in Figure 1. A list of the molecular ions ([M – H]⁻) found in the EamCE and the proposed tentative identification is given in Table 2. Twenty-one compounds were identified and characterized on the basis of their MS and MS/MS data (Figure 1).
Table 2. RP–UHPLC–ESI–QTOF–MSn data of flavonoids and phenolic acids identified in the aerial parts of *E. alata* monjauzeana.

| Peak | Compounds                                      | Rt (min) | Molecular Formula | m/z Experimental | m/z Calculated | Ionization Mode | Error   | Major Fragments (Intensity %) m/z |
|------|-----------------------------------------------|----------|-------------------|------------------|---------------|----------------|---------|---------------------------------|
| 1    | Caffeic acid                                  | 1.90     | C₆H₄O₆            | 179.0558         | 179.0561      | N              | 1.82    | 135 (6.7)                       |
| 2    | Gallic acid                                   | 4.37     | C₇H₆O₅            | 169.0143         | 169.0142      | N              | −0.39   | 125 (85), 79 (100)              |
| 3    | (epi)gallocatechin                            | 6.238    | C₁₀H₉O₅           | 305.0668         | 305.0667      | N              | −0.29   | 125 (3.69)                      |
| 4    | Catechin-O-hexoside                           | 8.222    | C₂₁H₂₂O₁₇         | 451.1243         | 451.1246      | N              | 0.51    | 289 (10.41)                     |
| 5    | o-Coumaric acid glucoside                     | 8.594    | C₁₀H₁₈O₆          | 325.0928         | 325.0929      | N              | 3.32    | 290 (15.02), 145 (8.31), 93 (57.82) |
| 6    | Quercetin-3-O-rhamnoside-7-O-glucoside        | 8.718    | C₂₁H₂₁O₁₂         | 609.1465         | 609.1461      | N              | −0.53   | 462 (1.82)                      |
| 7    | Apigenin-6,8-C-dihexoside                     | 9.462    | C₂₀H₁₈O₁₈         | 593.1523         | 593.1512      | N              | −1.64   | 473 (53), 383 (26), 353 (44)    |
| 8    | Epi-catechin                                  | 9.895    | C₁₅H₁₄O₆          | 289.0718         | 289.0718      | N              | 0.23    | 245 (3.8)                       |
| 9    | Apigenin-6-C-pentoside-8-C-hexoside           | 10.39    | C₂₁H₂₂O₁₄         | 563.1413         | 563.1413      | N              | −0.99   | 473 (1.1)                       |
| 10   | Rutin                                         | 10.94    | C₂₂H₂₃O₁₆         | 609.1468         | 609.1468      | N              | −1.05   | 300 (26)                        |
| 11   | myricetin-O-hexoside                          | 11.507   | C₂₁H₂₂O₁₉         | 479.0835         | 479.0831      | N              | −0.55   | 317 (6.45)                      |
| 12   | Quercetin-O-rhamnoside                        | 11.817   | C₂₁H₂₂O₁₁         | 447.0938         | 447.0933      | N              | −1.14   | 300 (3.61), 173 (11.85), 111 (10.77) |
| 13   | Hyperoside                                    | 12.313   | C₂₁H₂₂O₁₂         | 463.0885         | 463.0882      | N              | −0.36   | 300 (4.31), 271 (1.09)          |
| 14   | Luteolin-8-C-glucoside                        | 12.994   | C₂₁H₂₂O₁₃         | 447.0935         | 447.0938      | N              | −0.38   | 429 (1.82)                      |
| 15   | Quercetin-3-O-galactoside                     | 13.118   | C₂₁H₂₂O₁₂         | 463.0888         | 463.0882      | N              | −1.25   | 301 (4.54)                      |
| 16   | Verbasoside                                   | 13.181   | C₂₂H₂₂O₁₇         | 623.1256         | 623.1254      | N              | −0.26   | 461 (4.74)                      |
| 17   | Isorhamnetin-3-O-glucoside                    | 13.490   | C₂₁H₂₂O₁₂         | 477.1043         | 477.1038      | N              | −0.6    | 300 (5.18)                      |
| 18   | Naringenin-O-hexoside                         | 13.676   | C₂₁H₂₂O₁₀         | 433.1134         | 433.114       | N              | 0.91    | 271 (15.2)                      |
| 19   | Kaempferolrhamnoside                          | 14.792   | C₂₁H₂₂O₁₀         | 431.0986         | 431.0984      | N              | −0.5    | 285 (4.74)                      |
| 20   | Quercetin-3-O-glucoside                       | 14.91    | C₂₁H₂₂O₁₂         | 463.0883         | 463.0882      | N              | −0.02   | 300 (39)                        |
| 21   | Luteolin                                      | 19.68    | C₁₅H₁₀O₆          | 285.0406         | 285.0405      | N              | −0.57   | 133 (2)                         |
The quantification of both EamCE phenolic and flavonoid contents, additionally, to calibration curves of gallic acid and quercetin are shown in Figure 2.

Figure 2. TPC and TFC results. TPC is expressed as µg gallic acid equivalents/mg of extract (µg GAE/mg). TFC is expressed as µg quercetin equivalents/mg of extract (µg QE/mg).

Results of in vitro antioxidant and anti-enzymatic tests are reported as the mean values ± SD of three measurements; the IC₅₀ and A₀.5 values were calculated by linear regression analysis and are summarized in Tables 3 and 4, respectively. The EamCE SPF value is demonstrated in Table 5, with reference product SPF values.

Table 3. Antioxidant potentials with IC₅₀ and A₀.5 values.

| Products          | DPPH (IC₅₀) (µM) | ABTS (IC₅₀) (µM) | CUPRAC (IC₅₀) (µM) | BHA (IC₅₀) (µM) | BHT (IC₅₀) (µM) | Trolox (IC₅₀) (µM) | Kojic acid (IC₅₀) (µM) | Acarbose (IC₅₀) (µM) | Carotene (IC₅₀) (µM) | Orlistat (IC₅₀) (µM) | β-Amylase (IC₅₀) (µM) |
|-------------------|------------------|------------------|--------------------|-----------------|-----------------|-------------------|------------------------|-----------------------|----------------------|----------------------|----------------------|
| EamCE             | 32.49 ± 0.40 a    | 11.77 ± 0.41 a   | 25.71 ± 1.64 b     | 6.14 ± 0.41 c   | 12.99 ± 0.68 c  | 5.12 ± 0.49 a     | 25.23 ± 0.78 b        | 3650.93 ± 10.70 b     | 380.96 ± 2.38 b       | 38.04 ± 10.70 b      | 38.57 ± 1.44 a        |
| BHT *             | 12.98 ± 0.41 b    | 1.29 ± 0.20 b    | 8.97 ± 3.94 b      | NT              | NT              | NT                | NT                     | NT                    | NT                   | NT                   | NT                   |
| BHA *             | 6.14 ± 0.41 e     | 1.81 ± 0.10 e    | 5.31 ± 0.71 e      | NT              | NT              | NT                | NT                     | NT                    | NT                   | NT                   | NT                   |
| α-Tocopherol *    | 15.02 ± 2.17 d    | NT               | 34.93 ± 2.30 b     | NT              | NT              | NT                | NT                     | NT                    | NT                   | NT                   | NT                   |
| Ascorbic Acid *   | NT               | 6.31 ± 0.15 d    | 6.77 ± 1.15 c      | NT              | NT              | NT                | 7.14 ± 1.05 b         | 3.16 ± 0.02 d         | 3.02 ± 0.01 d         | 32.33 ± 1.17 b        |
| Tannic Acid *     | NT               | NT               | 5.20 ± 0.91 d      | NT              | NT              | NT                | NT                     | NT                    | NT                   | NT                   | NT                   |
| Trilobus *        | 5.12 ± 0.21 e     | 3.21 ± 0.16 d    | 8.69 ± 0.14 e      | 5.25 ± 0.21 e   | NT              | NT                | 34.17 ± 1.25 e        | 5.21 ± 0.27 e         | 4.31 ± 0.05 e         | NT                   | NT                   |

* Standard compounds. NT: not tested. IC₅₀ and A₀.5 values are defined as the concentration of 50% inhibition percent and the concentration at 0.50 absorbance, respectively. IC₅₀ and A₀.50 were calculated by linear regression analysis and expressed as mean ± SD (n = 3). The values with both superscripts (a, b, c, d, e) in the same columns are significantly different (p < 0.05).

Table 4. Anti-enzymatic results (IC₅₀ µg/mL).

| Products         | Anti-ACh (IC₅₀) (µM) | Anti-BChE (IC₅₀) (µM) | Anti-α Amylase (IC₅₀) (µM) | Anti-Tyrosinase (IC₅₀) (µM) | Anti-Urease (IC₅₀) (µM) | Anti-Lipase (IC₅₀) (µM) |
|------------------|----------------------|-----------------------|---------------------------|----------------------------|-------------------------|-------------------------|
| EamCE            | 22.46 ± 0.91 a       | 28.91 ± 1.08 a        | 22.66 ± 0.17 a            | 38.04 ± 0.98 a            | 23.55 ± 1.04 a          | 54.93 ± 0.17 a          |
| Galantamine *    | 6.27 ± 1.15 b        | 34.75 ± 1.99 b        | 34.75 ± 1.99 b            | 23.55 ± 1.04 a            | Na                      | Na                      |
| Acarbose *       | Na                   | Na                    | Na                        | Na                         | Na                      | Na                      |
| Kojic acid *     | Na                   | Na                    | Na                        | Na                         | Na                      | Na                      |
| Thioare *        | Na                   | Na                    | Na                        | Na                         | 11.57 ± 0.68 b          | Na                      |
| Orlistat *       | Na                   | Na                    | Na                        | Na                         | Na                      | 0.061 ± 0.001 b         |

* Standard compounds. IC₅₀ is defined as the concentration of 50% inhibition percentage. Na: no activity. IC₅₀ was calculated by linear regression analysis and expressed as mean ± SD (n = 3). The values with both superscripts (a, b) in the same columns are significantly different (p < 0.05).
Table 5. The EamCE photoprotective activity.

| Wavelength (nm) | EamCE (±SD) | Nivea (±SD) | Vichy (±SD) |
|----------------|-------------|-------------|-------------|
| 290            | 0.53 ± 0.01 | 0.77 ± 0.00 | 0.66 ± 0.00 |
| 295            | 2.75 ± 0.04 | 4.48 ± 0.00 | 3.64 ± 0.01 |
| 300            | 8.94 ± 0.24 | 14.39 ± 0.00 | 12.67 ± 0.10 |
| 305            | 9.37 ± 0.35 | 16.17 ± 0.23 | 14.47 ± 0.11 |
| 310            | 5.01 ± 0.17 | 9.35 ± 0.28 | 8.25 ± 0.08 |
| 315            | 2.13 ± 0.08 | 4.04 ± 0.00 | 3.69 ± 0.01 |
| 320            | 0.43 ± 0.01 | 0.87 ± 0.02 | 0.80 ± 0.00 |
| SPF            | 29.20 ± 0.92 | 50.10 ± 0.53 | 44.22 ± 0.34 |

* Reference compounds.

In regard to antioxidant EamCE potential, in almost all tests, the IC\textsubscript{50} and A0.50 values were close to the standard ones, except for the beta-carotene bleaching test and hydroxyl scavenging assays, that showed moderate effects.

Similarly, for the anti-enzymatic activities, the EamCE IC\textsubscript{50} value was less than the standard one for anti-BChE test and very near for the anti-AChE test. However, using the alpha amylase test, the reaction of the EamCE gave the best response, with a much lower IC\textsubscript{50} value than that of acarbose. In addition, the anti-urease and anti-tyrosinase IC\textsubscript{50} values were also very near to those of the reference compounds. For the anti-lipase test, the EamCE has exhibited an interesting inhibiting effect of 50% of lipase available in the mixture, with only 50 µg/mL (Table 4).

The heat-induced hemolysis (in-vitro anti-inflammatory test) results are illustrated in Table 6, where the EamCE has given a favorable activity. Finally, cytotoxic activity was expressed by the calculation of the inhibition percentage of cancerous cell lines. Effectively, no sufficient cell killing potential was recorded. The results are presented in Table 7.

Table 6. Heat induced hemolysis (percentage inhibition of hemolysis).

| Concentration (µg/mL) | Diclofenac % Inhibition | EamCE % Inhibition |
|-----------------------|-------------------------|--------------------|
| 65.5                  | 73.87 ± 1.86 \(^a\)     | 76.76 ± 0.15 \(^a\) |
| 32.75                 | 72.05 ± 0.64 \(^a\)     | 76.11 ± 2.08 \(^b\) |
| 16.375                | 72.03 ± 0.49 \(^a\)     | 74.92 ± 1.21 \(^b\) |
| 8.1875                | 70.23 ± 0.99 \(^a\)     | 71.03 ± 1.38 \(^b\) |

The inhibition % of hemolysis is expressed as mean ± SD (n = 3). The values with different superscripts (\(^a\), \(^b\)) in the same line are significantly different (p < 0.05), and the values with the same superscripts (\(^a\), \(^b\)) are not significantly different (p > 0.05).

Table 7. The EamCE percentage inhibition of HEP2 and RD cell lines.

| Concentration (µg/mL) | HEP2 (% Inhibition) | RD (% Inhibition) |
|-----------------------|---------------------|-------------------|
|                       | 48 h                | 72 h              | 48 h                | 72 h |
| 500                   | 25.25 ± 0.06 \(^a\) | 28.56 ± 0.05 \(^a\) | 7.20 ± 0.04 \(^a\) | 12.56 ± 0.45 \(^a\) |
| 250                   | 22.02 ± 0.06 \(^b\) | 22.87 ± 0.05 \(^b\) | 6.4 ± 0.21 \(^b\)  | 9.67 ± 0.23 \(^b\)  |
| 125                   | 19.78 ± 0.04 \(^c\) | 19.32 ± 0.04 \(^c\) | 3.02 ± 0.06 \(^c\) | 5.11 ± 0.94 \(^c\)  |
| 62.5                  | 6.74 ± 0.05 \(^d\)  | 10.8 ± 0.08 \(^d\) | 1.22 ± 0.05 \(^d\) | 3.42 ± 0.12 \(^d\)  |
| 31.25                 | 2.81 ± 0.01 \(^e\)  | 10.23 ± 0.05 \(^e\) | 0 \(^e\)           | 1.11 ± 0.02 \(^e\)  |
| 15.625                | 0 \(^f\)            | 9.52 ± 0.07 \(^f\) | 0 \(^f\)           | 0 \(^f\)           |

IC\textsubscript{50} are expressed as mean ± SD (n = 3). The values with different superscripts (\(^a\), \(^b\), \(^c\), \(^d\), \(^e\), \(^f\)) in the same columns are significantly different (p < 0.05).

4. Discussion

The identified phenolic compounds of the EamCE were categorized into three classes: phenolic acids, phenylpropanoids, and flavonoids.
Three compounds corresponding to peaks 1, 2, and 5 (caffeic acid [40], gallic acid [13], and O-coumaric acid glucoside [41] (glycosylated)) are phenolic acids. Only compound 16 has been identified as a phenylpropanoid [40].

Many different flavonoids have been found, some of them belonging to the subclass of flavonols, and they were allocated to glycosylated compounds; we identified: myricetin-O-hexoside [42], quercetin-O-rhamnoside [43], hyperoside [44], quercetin-3-O-galactoside [45], isorhamnetin-3-O-glucoside [44], kaempferol rhamnoside [41], quercetin-3-O-galactoside [46] (corresponding to peaks 11, 12, 13, 15, 17, 19, 20, respectively). Di-glycosylated flavonols were also found in peaks 6 and 10 (quercetin 3-O-rhamnoside-7-O-glucoside [47], rutin [44]).

Besides, the flavones were di-glycosylated compounds, namely apigenin-6,8-C-dihexoside [42] (peak 7), apigenin 6-C-pentoside-8-C-hexoside [47] (peak 9), glycosylated compound that was designated as luteolin 8-C-glucoside [47] (peak 14), and to non-glycosylated compound, which is the last flavone “luteolin” [42] (peak 21).

Likewise, the analysis has shown the presence of three flavan-3-ols that are recorded in peaks 3, 4, and 8, appropriately: (epi)gallocatechin [41], catechin-O-hexoside (glycosylated) [42], and epi-catechin [48].

Only one structure was defined as flavanone “naringenin-O-hexoside” (peak 18) [42].

Numerous studies have affirmed the presence of phenolic acid and flavonoid compounds in different Ephedra species, notably E. alata. These compounds act as the main contributors to the antioxidant potential and to many other biological activities of plant extracts [12,49,50]. Flavonoids are the most common class of secondary metabolites within the genus of Ephedra, and over forty flavonoids have been classified as flavonols, dihydroflavonols, flavonones, flavones, and anthocyanins; notably, flavones and their glycosides, as well as flavonols and their 3-O-glycosides constituents, are the most common flavonoids in Ephedra [51]. It has been discovered in Ephedra species that certain glycans (ephedran A, B, C, D, and E) occurred in the aerial parts, and diverse flavonols were identified to be components of twigs and barks [52]. Furthermore, several additional secondary metabolites originating from the molecular identification of different Ephedra species in previous studies included alkaloids, amino acids and derivatives, volatiles, and phenolic compounds. The alkaloids were of significant biological relevance: ephedrine, pseudoephedrine, norephedrine, norpseudoephedrine, methylephedrine, and methylpseudoephedrine. Other alkaloids have been detected in some Eurasian Ephedra species, such as: ephedroxane and macrocyclic spermidines called ephedradine A–D [53]; nevertheless, they were not found in our plant.

The TPC and TFC analyses have shown that the EamCE possesses a considerable amount of phenolic and flavonoid compounds, which are higher than the ones found in other studies of the same plant species [54]. The plausible antioxidant potential of a bioactive product can be estimated by distinct in vitro assays based on the inhibition ability of consistent free radicals [55]. To that end, we have proceeded by several distinct antioxidant tests with direct, indirect, or competitive procedures, reduction, chelation, or inhibition principles. We believe that the ten tested methods could ensure the antioxidant properties of the EamCE, even if it gives a medium potential for one of them. Effectively, the EamCE has provided a very powerful antioxidant activity, and the IC$_{50}$ and A0.5 concentrations shown in Table 3 were relatively low and approximately the same order of magnitude than the standard ones (except for the β-carotene bleaching and hydroxyl scavenging assays). Presumably, the quantity of the molecule responsible of the effect is lower, if not considering that the measured activity was a result of the synergic effect of many combined molecules, even though the EamCE abilities to act as an antioxidant product remained very substantial and neighboring those of reference compounds. The EamCE demonstrated a strong antioxidant capacity with lower DPPH IC$_{50}$ (µg/mL) and reducing power A0.5 (µg/mL) values comparatively to other extracts from E. alata, E. alata Campylopoda Fragilis (ECF), Procura fisch. et may (EPfm), and sarcocarpa (Es) species of different previous studies. Indeed, DPPH IC$_{50}$ from E. alata extract was >1000, 83.07 ± 0.2 [49], 330 ± 0.004, 454 ± 0.008, 180 ± 0.002, 176 ± 0.002 [12], 450 ± 7, 540 ± 3.455 ± 6 [42]. DPPH IC$_{50}$ (µg/mL) from ECF extracts was
DPPH IC$_{50}$ (µg/mL) from EPfm extract was $300 \pm 4.4$, $150 \pm 5.1$, $125 \pm 4.4$ [56,57]; and DPPH IC$_{50}$ (µg/mL) from Es extract was $5300 \pm 0.027$ [58]. Moreover, reducing power A0.5 (µg/mL) from E. alata plant extracts was $108 \pm 1$ [50], $377 \pm 4$ [42]. Referring to earlier antioxidant studies of E. alata species or other species, none of them have used ten different antioxidant methods to demonstrate how powerful and strongly bioactive is the extract of interest. The exhibited prominent antioxidant activity of the EamCE enables us to consider it as a very promising product that could be involved in the resolution of many physiological disorders related to oxidant antioxidant imbalances and oxidative stress that induce the development of others serious pathologies.

For the current time, we hardly found reports about enzymatic inhibition properties for the family of Ephedra and its species; we aimed across this work to reveal the ability of this plant to block the catalytic site of distinct enzymes. Therefore, it would be valuable and relevant for application in the context of pathologic dysfunction of the enzymes in question.

Today, the neurodegenerative disorder Alzheimer’s disease is more frequent in older people worldwide, and the conception of efficient treatments requires a perfect awareness of the physiological mechanisms involved [59]. An AChE hyperactivity was mentioned in the brain of Alzheimer affected subjects, particularly in the senile plaque-rich fraction [60]. AChE preponderates in the healthy brain, contrary to BChE, that slightly influences the regulation of brain acetylcholine amounts. However, BChE activity progressively increases in patients with AD. Both enzymes constitute legitimate therapeutic targets for enhancing the cholinergic deficit causing the decline in cognitive, behavioral, and global functioning features of AD [61]. The EamCE has showed an impressive inhibitory potential (Table 4) of both AChE and BChE enzymes, particularly for the BChE blocking effect, that has given an IC$_{50}$ (µg/mL) value ($28.91 \pm 1.08$) better than that of galantamine ($34.75 \pm 1.99$). This leads us to fully consider that the chemical constituents are sufficiently able to act as AChE and BChE antagonists; by the same token, researchers have already proven that selected phenolic acids and flavonoids exhibited an important inhibitory activity towards AChE and BChE, and these compounds are in common with the chemical constitution of the EamCE, for instance: caffeic acid, gallic acid, apigenin, quercetin, luteolin, and kaempferol [62,63].

Diabetes is a metabolic dysfunction defined by chronic hyperglycaemia. It exists several and various medical approaches for the cure of type 2 diabetes. The inhibition of alpha-amylase activity is only one way to downregulate postprandial blood glucose levels [64,65]. The inhibitors of this enzyme can be used in the treatment of obesity and diabetes. In diabetic patients, it catalyzes the hydrolysis of α-(1,4)-β-D-glycosidic linkages of starch and other glucose polymers. The inhibition of α-amylase prevents starch breaking and results in lower levels of blood glucose [66]. A previous study has demonstrated the role of flavonoids in the inhibition of alpha-amylase activity, and it has also qualified the common flavonol myricetin (one of the EamCE components) as a strong flavonoid inhibitor of α-amylase and considered the possibility to deliver it in concentrated form (capsules with food intake) to reduce postprandial hyperglycaemia (by inhibiting starch digestion) [67]. The action mechanism proposed for the inhibitory ability of flavonoids is associated with the number of hydroxyl groups on the B ring of the flavonoid skeleton, the formation of hydrogen bonds between the hydroxyl groups of the polyphenol ligands, and the catalytic residues of the binding site of the enzyme [68]. The important inhibitory ability is noticed in flavonols and flavones groups [68–70]. Our finding is in agreement with the preceding ones; the EamCE has presented an impressive antidiabetic activity that was more efficient than the one of acarbose, and we have noted a very large difference comparing their IC$_{50}$ (µg/mL): $22.66 \pm 0.17$, $3650.93 \pm 10.70$, respectively.

Tyrosinase is a crucial enzyme of melanin metabolism implicated in identifying the color of mammalian skin and hair. The accumulation of an excessive level of epidermal pigmentation, due to tyrosinase hyperactivity, causes different dermatological disorders, such as melasma, age spots, and sites of actinic damage, besides the unfavorable enzymatic browning of plant-derived foods that induce the decrease in nutritional quality and economic loss of food products [71]. Previously, enzyme kinetics and molecular docking
techniques were used to examine the inhibitory capacity and the structural mechanism of flavonoids on tyrosinase; according to the obtained favorable results, authors suggested that flavonoids containing an additional hydroxyl group at the C-3′ position, and especially a 3′,4′-dihydroxyl substitution on ring B, increase tyrosinase inhibitory effects and can be considered as potential candidates for the design of tyrosinase inhibitor drug [72]. Since the EamCE contained high concentrations of flavonoids, it has exhibited a remarkable tyrosinase blocking activity.

Inhibition of the metalloenzyme urease has considerable pharmacological utilizations in the matter of antiulcer and anti-gastric cancer drugs. Urease is involved in many serious infections caused by *Helicobacter pylori* in the gastric tract, as well as by *Proteus* and related species in the urinary tract [73]. In a similar manner to other enzymatic inhibitory activities, the EamCE has demonstrated a blocking property of the urease catalytic site.

Obesity is a multifactorial pathology defined by an overweight to height ratio, depending on an intensified fat deposition, such as adipose tissue, which is related to more excessive calorie consumption than energy expenditure [74]. The imbalance between calorie consumption and metabolic expenditure is a central factor in several cases of obesity, and reduction in the intake of energy dense fats may be useful to reduce weight; therefore, the suppression of energy intake by inhibiting the action of pancreatic lipase that splits triglycerides into absorbable glycerol and fatty acids could be a useful strategy [75]. Phytochemicals identified from traditional medicinal plants are biologically active and can act as antiobesity agents. Various plants have been screened for their anti-lipase activity due to the abundance of inhibitors from different chemical classes: saponins, polyphenolics, terpenes and triterpenes [74,76]. Orlistat is an antiobesity agent, which selectively and potently inhibits the absorption and the hydrolysis of fat that results in 30% decrease in fat absorption [77]. In our work, it has given (orlistat) an outstanding effect (IC$_{50}$: 0.061 ± 0.001 µg/mL); however, the EamCE was not that efficient, but it has performed a remarkable and distinguishing anti-lipase potential comparatively to plenty of other plant extracts that have exhibited low effectiveness in many potent anti-obesity agents reports [78–84].

Long exposure to UV radiation increases the risk of skin diseases, such as cancer and photoallergic reactions. UV-B (280–320 nm) radiation is mainly responsible for inducing skin problems. Natural substances have been recently considered as potential sunscreen resources due to their absorption in the UV region and their antioxidant activity. Clearly, a good correlation was found between SPF and phenolic contents of plant extracts [85], due to that fact the EamCE has given an important index of photo screening estimated by an SPF of 29.20 ± 0.92, which is considered moderate, but not negligible, comparatively with commercial and cosmetic sun screen SPF values (Table 5).

Recent findings have demonstrated that quercetin-rich methanol extract of *Ephedra ciliata* has an anti-inflammatory activity, which promoted the healing of wounds in two different models, and, at cytokine reduced amount, the downregulation of TNF-α was suggested as the inducer factor of the anti-inflammatory and wound healing activity [86]. Critical compounds of *Ephedra*, including quercetin, luteolin, kemperol, naringenin, and beta-sitosterol, were identified in treating asthma by inhibiting the expression of many anti-inflammatory targets, SELE, IL-2, and CXCL10, at mRNA and protein levels; these substances are involved in the biological processes of immune response, inflammatory response, cell-cell signaling, and response to lipopolysaccharide [87]. In our anti-inflammatory approach, the EamCE has provided a convincing ability to inhibit hemolysis induced by heating. The percentage of inhibition was very high, at 76.76 ± 0.15%, and, at a very low concentration of the EamCE (65.5 µg/mL), it has shown the same effect as the anti-inflammatory drug used as a reference (Diclofenac), notably at the same concentration. Clearly, the effect has not been reduced, even in low concentration (71.03 ± 1.38% at 8.1875 µg/mL), as shown in Table 6, and we proclaim that this eminent effect is due to the presence of the affirmed anti-inflammatory compounds discussed in the above research works.
A recent in-depth analysis reported on the screening of extracts from 57 plants for checking the relationship between free radical scavenging and cytotoxicity. The results revealed that the extracts of plants exhibited an EC_{50} of free radical scavenging ≤10 μg/mL showed a degree of enhancement in increased cytotoxicity [88].

Some compounds isolated from Ephedra extracts of different species, such as herbacetin, ephedrine alkaloids, and oligomeric proanthocyanidins, have exerted a putative antiproliferative potential against different cancer cell lines [51]. The criteria of cytotoxic activity for the crude extracts, as handled by the American National Cancer Institute, is an IC_{50} < 30 μg in the preliminary assay [89]. Consequently, we consider that the EamCE is not an interesting anticancer agent, contrary to other crude extracts from E. alata (possessing a powerful anticancer activity) [10,49,54]. The EamCE has given about 20% as an inhibition percentage at the extreme concentration of (500 μg/mL), and the same effect remained and did not change after 72 h (Table 7). This is maybe due to the non-existence of specific Ephedra alkaloids that engender the pharmacological and toxicological effects and induce metabolic pathways occurring in particular Ephedra species [53].

5. Conclusions

The prominent antioxidant, anti-enzymatic (neuroprotective, anti-diabetic, dermoprotective, anti-infectious, anti-obesity), and anti-inflammatory in vitro effects exerted by the EamCE parallel its rich chemical arsenal. The chemical profile is individualized by the identified flavonoids and phenolic acids (phenolic acids, phenylpropanoids, flavonoids, flavones, flavanols, flavanones). The latter are the potential candidates of the current proven biological activities, as well as its tolerable non-cytotoxicity.

The present outcomes highlight E. alata monjauzeana as a putative promising natural source to design food additives as a spice, preservative, essential oil, etc. Otherwise, it could be used as a dietary supplement, acting as therapeutic agent for a wide array of human illnesses or cosmetic products (such as sunscreen), with no harmful side effects.

Author Contributions: Conceptualization, L.K., T.B. and M.M.B.; Methodology, L.K., T.B. and M.M.B.; Software, L.K. and T.B.; Validation, T.B., M.M.B., A.C., F.C., S.A. and G.N.; Formal Analysis, L.K., T.B., M.M.B. and J.L.-S.; Investigation, L.K., T.B., M.M.B. and J.L.-S.; Resources, H.C. and A.S.-C.; Data Curation, L.K., M.M.B. and F.C.; Writing—Original Draft Preparation, L.K.; Writing—Review & Editing, L.K.; Visualization, A.C. and S.A.; Supervision, H.C., A.S.-C., S.A.; Project Administration, T.B. and A.C.; Funding Acquisition, G.N. All authors listed have made a substantial, direct and intellectual contribution to the work and approved the work for publication. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We gratefully thank the Algerian Ministry of Higher Education and Scientific Research and the Algerian General Directorate of Scientific Research and Technological Development for the availability and the open doors of their research institutions.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Phillipson, J. Phytochemistry and medicinal plants. Phytochemistry 2001, 56, 237–243. [CrossRef]
2. Lemma, D.T.; Banjaw, D.T.; Megersa, H.G. Micropropagation of Medicinal Plants: Review. Int. J. Plant Breed. Crop Sci. 2020, 7, 796–802.
3. Salmeron-Manzano, E.; Garrido-Cardenas, J.A.; Manzano-Agugliaro, F. Worldwide Research Trends on Medicinal Plants. Int. J. Environ. Res. Public Health 2020, 17, 3376. [CrossRef]
4. Jaradat, N.; Hussen, F.; Ali, A.A. Preliminary Phytochemical Screening, Quantitative Estimation of Total Flavonoids, Total Phenols and Antioxidant Activity of Ephedra alata Decne. J. Mater. Environ. Sci. 2015, 6, 1771–1778.
5. Soua, L.; Koubaa, M.; Barba, F.J.; Fakhfakh, J.; Ghamgui, H.K.; Chaabouni, S.E. Water-Soluble Polysaccharides from Ephedra alata Stems: Structural Characterization, Functional Properties, and Antioxidant Activity. *Molecules* **2020**, *25*, 2210. [CrossRef]

6. Al-Rimawi, F.; Abu-Lafi, S.; Abbadi, J.; Alamernah, A.A.; Sawahreh, R.A.; Odeh, I. Analysis of phenolic and flavonoids of wild Ephedra alata plant extracts by LC/PA and LC/MS and their antioxidant activity. *Afr. J. Tradit. Complement. Altern. Med.* **2017**, *14*, 130–141. [CrossRef]

7. Demmers, A.; Korthout, H.; Van Etten-Jamaludin, F.S.; Kortekaas, F.; Maaskant, J.M. Effects of medicinal food plants on impaired glucose tolerance: A systematic review of randomized controlled trials. *Diabetes Res. Clin. Pr.* **2017**, *131*, 91–106. [CrossRef]

8. Der Marderosian, A.H.; Hauke, R.L.; Youngken, H.W., Jr. The identification of certain “medicinal” plant families. *Econ. Bot.* **1964**, *18*, 158–163. [CrossRef]

9. Merola, N.; Castillo, J.; Benavente-García, O.; Ros, G.; Nieto, G. The Effect of Consumption of Citrus Fruit and Olive Leaf Extract on Lipid Metabolism. *Nutrients* **2017**, *9*, 1062. [CrossRef] [PubMed]

10. Nieto, G. A Review on Applications and Uses of Thymus in the Food Industry. *Plants* **2020**, *9*, 961. [CrossRef] [PubMed]

11. Caveney, S.; Charlet, D.A.; Freitag, H.; Maier-Stölte, M.; Stärrett, A.N. New observations on the secondary chemistry of world Ephedra (Ephedraceae). *Am. J. Bot.* **2001**, *88*, 1199–1208. [CrossRef] [PubMed]

12. Mighri, H.; Akrout, A.; Bennour, N.; Eljeni, H.; Neffati, M. LC/MS method development for the determination of the phenolic compounds of Tunisian Ephedra alata hydro-methanolic extract and its fractions and evaluation of their antioxidant activities. *S. Afr. J. Bot.* **2019**, *124*, 102–110. [CrossRef]

13. Danciu, C.; Muntean, D.; Alexa, E.; Farcas, C.; Opren, C.; Zupko, I.; Bor, A.; Minda, D.; Proks, M.; Buda, V.; et al. Phytochemical Characterization and Evaluation of the Antimicrobial, Antiproliferative and Pro-Apoptotic Potential of Ephedra alata Decne. Hydroalcoholic Extract against the MCF-7 Breast Cancer Cell Line. *Molecules* **2018**, *24*, 13. [CrossRef] [PubMed]

14. Hegazi, G.A.E.-M.; El-Lamey, T.M. In Vitro Production of Some Phenolic Compounds from Ephedra alata Decne. *J. Appl. Environ. Biol. Sci.* **2011**, *1*, 158–163.

15. International Plant Names Index. Nouvelle Flore de l’Algérie et des Régions Désertiques Meridionales. *Paris*. Available online: https://www.ipni.org/p/20008139-1 (accessed on 10 November 2021).

16. Singleton, V.L.; Rossi, J.A. Colorimetry of Total Phenolics with Phosphomolybdic-Phosphotungstic Acid Reagents. *Am. J. Enol. Vitic.* **1965**, *16*, 144–158.

17. Müller, L.; Gnoyke, S.; Popken, A.M.; Böhm, V. Antioxidant capacity and related parameters of different fruit formulations. *LWT—Food Sci. Technol.* **2010**, *43*, 992–999. [CrossRef]

18. Topçu, G.; Aky, M.; Bilici, A.; Sarikurkcu, C.; Oztürk, M.; Ulubelen, A. A new flavone from antiseptic extracts of Pistacia terebinthus. *Food Chem.* **2007**, *103*, 816–822. [CrossRef]

19. Re, R.; Pellegrini, N.; Proteggente, A.; Pannala, A.; Yang, M.; Rice-Evans, C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free Radic. Biol. Med.* **1999**, *26*, 1231–1237. [CrossRef]

20. Blois, M.S. Antioxidant Determinations by the Use of a Stable Free Radical. *Nature* **1958**, *181*, 1199–1200. [CrossRef]

21. Kunchandy, E.; Rao, M.N.A. Oxygen radical scavenging activity of curcumin. *Int. J. Pharm.* **1990**, *58*, 237–240. [CrossRef]

22. Oyaizu, M. Studies on products of browning reaction. Antioxidative activities of products of browning reaction prepared from glucosamine. *Jpn. J. Nutr. Diet.* **1986**, *44*, 307–315. [CrossRef]

23. Marco, G.J. A rapid method for evaluation of antioxidantants. *J. Am. Oil Chem. Soc.* **1968**, *45*, 594–598. [CrossRef]

24. Apak, R.; Güçlü, K.; Öztürk, M.; Karademir, S.E. Novel Total Antioxidant Capacity Index for Dietary Polyphenols and Vitamins C and E, Using Their Cupric Ion Reducing Capability in the Presence of Neocuproine: CURPAC Method. *J. Agric. Food Chem.* **2004**, *52*, 7970–7981. [CrossRef]

25. Smirnoff, N.; Cumbes, Q.J. Hydroxyl radical scavenging activity of compatible solutes. *Phytochemistry* **1989**, *28*, 1057–1060. [CrossRef]

26. Szydłowskakszczeniak, A.; Dianoczki, C.; Recseg, K.; Karlovits, G.; Szlyk, E. Determination of antioxidant capacities of vegetable oils by ferric-iron spectrophotometric methods. *Talanta* **2008**, *76*, 899–905. [CrossRef] [PubMed]

27. Shi, H.; Noguchi, N.; Niki, E. Galvinoxyl method for standardizing electron and proton donation activity. In *Methods in Enzymology*; Elsevier BV: Amsterdam, The Netherlands, 2001; Volume 335, pp. 157–166.

28. Öztürk, M.; Duru, M.E.; Kivrak, Ş.; Mercan-Doğan, N.; Türkoglu, A.; Özler, M.A. In vitro antioxidant, anticholinesterase and antimicrobial activity studies on three Agaricus species with fatty acid compositions and iron contents: A comparative study on the three most edible mushrooms. *Food Chem. Toxicol.* **2011**, *49*, 1353–1360. [CrossRef]
57. Dehkordi, N.V.; Kachouie, M.A.; Pirbalouti, A.G.; Malekpooor, F.; Rabiei, M. Total phenolic content, antioxidant and antibacterial activities of the extract of ephedra procer fisch. et mey. *Acta Pol. Pharm.* 2015, 72, 341–345.

58. Rustaiyan, A.; Javidinia, K.; Farjam, M.H.; Aboee-Mehrizi, F.; Ezzatzadeh, E. Antimicrobial and Antioxidant Activity of the *Ephedra sarcocarpa* Growing in Iran. *J. Med. Plants Res.* 2011, 5, 4251–4255.

59. Yoon, J.-C.; Lee, S.-R.; Jung, I.-C. The Effects of Hyung Bang 5a Baek-San (Jing Fang Xie Bai San) on the Alzheimer’s Disease Model Induced by βA. *J. Orient. Neuropsychiatr.* 2010, 21, 171–189.

60. Mimori, Y.; Nakamura, S.; Yukawa, M. Abnormalities of acetylcholinesterase in Alzheimer’s disease with special reference to effect of acetylcholinesterase inhibitor. *Behav. Brain Res.* 1997, 83, 25–30. [CrossRef]

61. Greig, N.H.; Lahiri, D.K.; Sambamurti, K. Butyrylcholinesterase: An Important New Target in Alzheimer’s Disease Therapy. *Int. Psychogeriatr.* 2002, 14, 77–91. [CrossRef]

62. Szważgier, D. Anticholinesterase activity of selected phenolic acids and flavonoids—Interaction testing in model solutions. *Ann. Agric. Environ. Med.* 2015, 22, 690–694. [CrossRef]

63. Orhan, I.; Kartal, M.; Tosun, F.; Şenler, B. Screening of Various Phenolic Acids and Flavonoid Derivatives for their Anticholinesterase Potential. *Z. Nat. C* 2007, 62, 829–832. [CrossRef]

64. Funke, I.; Melzig, M.F. Traditionally Used Plants in Diabetes Therapy—Phytotherapeutics as Inhibitors of α-Amylase Activity. *Rev. Bras. Farm.* 2006, 16, 1–5. [CrossRef]

65. Martínez, J.; Nieto, G.; Castillo, J.; Ros, G. Influence of in vitro gastrointestinal digestion and/or grape seed extract addition on antioxidant capacity of meat emulsions. *J. Food Res. Int.* 2020, 129, 108789. [CrossRef]

66. Mahmood, N. A review of α-amylase inhibitors on weight loss and glycemic control in pathological state such as obesity and diabetes. *Comp. Haematol. Int.* 2016, 25, 1253–1264. [CrossRef]

67. Gu, C.; Zhang, H.; Putri, C.; Ng, K. Evaluation of α-Amylase and α-Glucosidase Inhibitory Activity of Flavonoids. *Int. J. Food Nutr. Sci.* 2015, 2, 1–6. [CrossRef]

68. Sales, P.M.; Souza, P.; Simeoni, L.A.; Magalhães, P.O.; Silveira, D. α-Amylase Inhibitors: A Review of Raw Material and Isolated Compounds from Plant Source. *J. Pharm. Pharm. Sci.* 2012, 15, 141–183. [CrossRef]

69. Martínez, J.; Nieto, G.; Castillo, J.; Ros, G. Influence of in vitro gastrointestinal digestion and/or grape seed extract addition on antioxidant capacity of meat emulsions. *LWT—Food Sci. Technol.* 2014, 59, 834–840. [CrossRef]

70. Milla, P.; Peñalver, R.; Nieto, G. Health Benefits of Uses and Applications of *Moringa oleifera* in Bakery Products. *Plants* 2021, 10, 318. [CrossRef]

71. Kim, Y.-J.; Uyama, H. Tyrosinase inhibitors from natural and synthetic sources: Structure, inhibition mechanism and perspective for the future. *Cell. Mol. Life Sci.* CMLS 2005, 62, 1707–1723. [CrossRef]

72. Şöhretoglu, D.; Sari, S.; Barut, B.; Ozel, A. Tyrosinase inhibition by some flavonoids: Inhibitory activity, mechanism by in vitro and in silico studies. *Bioorg. Chem.* 2018, 81, 168–174. [CrossRef]

73. Hassan, S.T.S.; Žemlička, M. Plant-Derived Urease Inhibitors as Alternative Chemotherapeutic Agents: Plant-Derived Urease Inhibitors. *Arch. Pharm.* 2016, 349, 507–522. [CrossRef]

74. De La Garza, A.L.; Milagro, F.I.; Boque, N.; Campiñez, L.; Jongberg, S.; Ros, G.; Skibsted, L.H.; Nieto, G. Plant derived ingredients rich in nitrates or phenolics for protection of pork against protein oxidation. *Food Res. Int.* 2016, 89, 143–151. [CrossRef]

75. Al-Suwailem, A.; Al-Tamimi, A.; Al-Omar, M.; Al-Suhibani, M. Safety and Mechanism of Action of Orlistat (Tetrahydrolipstatin) as the First Local Antiobesity Drug. *J. Pharm. Pharm. Sci.* 2012, 15, 242–252. [CrossRef]

76. Birari, R.B.; Bhutani, K.K. Pancreatic lipase inhibitors from natural sources: Unexplored potential. *Drug Discov. Today* 2007, 12, 879–889. [CrossRef] [PubMed]

77. Al-Suwailem, A.; Al-Tamimi, A.; Al-Omar, M.; Al-Suhibani, M. Safety and Mechanism of Action of Orlistat (Tetrahydrolipstatin) as the First Local Antiobesity Drug. *J. Appl. Sci. Res.* 2006, 2, 205–208. [CrossRef]

78. Zeng, S.; Li, S.-Z.; Lai, C.-J.-S.; Wei, M.-Y.; Chen, B.-Z.; Li, P.; Zheng, G.-D.; Liu, E.-H. Evaluation of anti-lipase activity and bioactive flavonoids in the Citri Reticulatae Pericarpium from different harvest time. *Phytomedicine* 2018, 43, 103–109. [CrossRef] [PubMed]

79. Gulua, L.; Nikolashvili, L.; Jgenti, M.; Turmanidze, T.; Dzemlazde, G. Polyphenol content, anti-lipase and antioxidant activity of teas made in Georgia. *J. Appl. Sci. Res.* 2008, 16, 357–361. [CrossRef]

80. Turkiewicz, I.P.; Wojdylo, A.; Tkacz, K.; Nowicka, P.; Hernández, F. Antidiabetic, Anticholinesterase and Antioxidant Activity vs. Terpenoids and Phenolic Compounds in Selected New Cultivars and Hybrids of Artichoke *Cynara scolymus* L. *Molecules* 2019, 24, 1222. [CrossRef] [PubMed]

81. Nieto, G.; Xiong, Y.L.; Payne, F.; Castillo, M. Predicting frankfurters quality metrics using light backscatter. *J. Food Eng.* 2014, 143, 132–138. [CrossRef]

82. Martínez, J.; Nieto, G.; Ros, G.; Martínez, G.N. Total antioxidant capacity of meat and meat products consumed in a reference ‘Spanish standard diet’. *Int. J. Food Sci. Technol.* 2014, 49, 2610–2618. [CrossRef]

83. Echarte, M.; Conchillo, A.; Ansorena, D.; Astiasarán, I. Evaluation of the nutritional aspects and cholesterol oxidation products of pork liver and fish patés. *Food Chem.* 2004, 86, 47–53. [CrossRef]

84. Díaz, P.; Nieto, G.; Bañón, S.; Garrido, M.D. Determination of Shelf Life of Sous Vide Salmon (*Salmo salar*) Based on Sensory Attributes. *J. Food Sci.* 2009, 74, S371–S376. [CrossRef] [PubMed]
85. Ebrahimzadeh, M.A.; Enayatifard, R.; Khalili, M.; Ghaffarloo, M.; Saeedi, M.; Charati, J.Y. Correlation Between Sun Protection Factor and Antioxidant Activity, Phenol and Flavonoid Contents of Some Medicinal Plants. *Iran. J. Pharm. Res.* 2014, 13, 1041–1047. [PubMed]

86. Yaseen, H.S.; Asif, M.; Saadullah, M.; Mahrulk; Asghar, S.; Shams, M.U.; Bazmi, R.R.; Saleem, M.; Yousaf, H.M.; Yaseen, M. Methanolic extract of *Ephedra ciliata* promotes wound healing and arrests inflammatory cascade in vivo through downregulation of TNF-α. *Inflammopharmacology* 2020, 28, 1691–1704. [CrossRef] [PubMed]

87. Huang, X.-F.; Cheng, W.-B.; Jiang, Y.; Liu, Q.; Liu, X.-H.; Xu, W.-F.; Huang, H.-T. A network pharmacology-based strategy for predicting anti-inflammatory targets of ephedra in treating asthma. *Int. Immunopharmacol.* 2020, 83, 106423. [CrossRef] [PubMed]

88. Sammar, M.; Abu-Farich, B.; Rayan, L.; Falah, M.; Rayan, A. Correlation between Cytotoxicity in Cancer Cells and Free Radical-scavenging Activity: Invitro Evaluation of 57 Medicinal and Edible Plant Extracts. *Oncol. Lett.* 2019, 18, 6563–6571. [CrossRef] [PubMed]

89. Itharat, A.; Houghton, P.J.; Eno-Amooquaye, E.; Burke, P.; Sampson, J.H.; Raman, A. In vitro cytotoxic activity of Thai medicinal plants used traditionally to treat cancer. *J. Ethnopharmacol.* 2004, 90, 33–38. [CrossRef] [PubMed]